Jazz Nabs Novel Narcolepsy Drug From Sumitomo
And Diversifies Portfolio
The Ireland-headquartered firm will advance the candidate into US and EU narcolepsy studies as part of its pipeline diversification project as portfolio products are set to lose their patent exclusivity.
